Wyeth-Ayerst To Market Aviron's FluMist Worldwide

Wyeth Lederle Vaccines, a business unit of Wyeth-Ayerst Laboratories, has acquired exclusive worldwide rights to market Aviron's FluMist influenza vaccine. The therapy is currently under development for the prevention of influenza and its associated complications and has completed pivotal phase III clinical trials.

Under the terms of the agreement, Wyeth Lederle Vaccines and Aviron will co-promote FluMist in the U.S., while Wyeth will have the exclusive right to market the product outside the U.S. In each case, Wyeth will hold the marketing rights for up to 11 years. The collaboration excludes Korea, Australia, New Zealand and certain South Pacific countries.

For more information: Aviron, 297 N. Bernando Ave., Mountain View, CA 94043, USA. Telephone: 650-919-6500. Fax: 650-919-6610.